301 related articles for article (PubMed ID: 18761548)
1. Pompholyx after intravenous immunoglobulin therapy for treatment of Guillain-Barré syndrome.
Rhee DY; Park GH; Chang SE; Lee MW; Choi JH; Moon KC; Koh JK
J Eur Acad Dermatol Venereol; 2009 May; 23(5):602-4. PubMed ID: 18761548
[No Abstract] [Full Text] [Related]
2. [Eczematous reactions after intravenous immunoglobulin therapy in two patients with Guillain-Barré syndrome and a patient with Miller Fisher syndrome].
Tada M; Tada M; Ishiguro H; Yagi E; Hirota K
No To Shinkei; 2003 May; 55(5):401-5. PubMed ID: 12833881
[TBL] [Abstract][Full Text] [Related]
3. Pompholyx (vesicular eczema) after i.v. immunoglobulin therapy for neurologic disease.
Iannaccone S; Sferrazza B; Quattrini A; Smirne S; Ferini-Strambi L
Neurology; 1999 Sep; 53(5):1154-5. PubMed ID: 10496291
[No Abstract] [Full Text] [Related]
4. Severe dyshidrotic eczema after intravenous immunoglobulin therapy for Kawasaki syndrome.
Shiraishi T; Yamamoto T
Pediatr Dermatol; 2013; 30(3):e30-1. PubMed ID: 22304420
[TBL] [Abstract][Full Text] [Related]
5. Pompholyx after IV immunoglobulin therapy for neurologic disease.
Ikeda K; Iwasaki Y; Ichikawa Y; Kinoshita M
Neurology; 2000 May; 54(9):1879. PubMed ID: 10802813
[No Abstract] [Full Text] [Related]
6. Pompholyx induced by intravenous immunoglobulin therapy.
Llombart M; García-Abujeta JL; Sánchez-Pérez RM; Hernando de Larramendi C
J Investig Allergol Clin Immunol; 2007; 17(4):277-8. PubMed ID: 17694704
[No Abstract] [Full Text] [Related]
7. Intravenous immunoglobulin reduces serum tumor necrosis factor alpha in patients with Guillain-Barre syndrome.
Reuben S; Sumi MG; Mathai A; Nair MD; Radhakrishnan VV
Neurol India; 2003 Dec; 51(4):487-9. PubMed ID: 14742928
[TBL] [Abstract][Full Text] [Related]
8. Guillain-Barré syndrome associated with scrub typhus.
Lee SH; Jung SI; Park KH; Choi SM; Park MS; Kim BC; Kim MK; Cho KH
Scand J Infect Dis; 2007; 39(9):826-8. PubMed ID: 17701724
[TBL] [Abstract][Full Text] [Related]
9. [Guillain-Barré syndrome. What should be done, when the treatment appears to fail?].
Tellería-Díaz A
Rev Neurol; 2003 Oct 16-31; 37(8):798-800. PubMed ID: 14593645
[No Abstract] [Full Text] [Related]
10. Reversible posterior leukoencephalopathy, cerebral vasoconstriction, and strokes after intravenous immune globulin therapy in guillain-barre syndrome.
Doss-Esper CE; Singhal AB; Smith MS; Henderson GV
J Neuroimaging; 2005 Apr; 15(2):188-92. PubMed ID: 15746232
[TBL] [Abstract][Full Text] [Related]
11. Recurrent Guillain-Barre syndrome as a complication of immune reconstitution in HIV.
Makela P; Howe L; Glover S; Ferguson I; Pinto A; Gompels M
J Infect; 2002 Jan; 44(1):47-9. PubMed ID: 11972420
[No Abstract] [Full Text] [Related]
12. [Guillain-Barré syndrome].
Kusunoki S
Nihon Rinsho; 2005 May; 63 Suppl 5():427-31. PubMed ID: 15954387
[No Abstract] [Full Text] [Related]
13. Immunotherapy for Guillain-Barré syndrome in the US hospitals.
Alshekhlee A; Hussain Z; Sultan B; Katirji B
J Clin Neuromuscul Dis; 2008 Sep; 10(1):4-10. PubMed ID: 18772694
[TBL] [Abstract][Full Text] [Related]
14. A rare case of Guillain-Barre syndrome with pregnancy.
Vijayaraghavan J; Vasudevan D; Sadique N; Rajeswari KS; Pondurangi M; Jayshree
J Indian Med Assoc; 2006 May; 104(5):269-70. PubMed ID: 17058576
[TBL] [Abstract][Full Text] [Related]
15. Immune supplementation and immune modulation with intravenous immunoglobulin.
Mazer BD; Al-Tamemi S; Yu JW; Hamid Q
J Allergy Clin Immunol; 2005 Oct; 116(4):941-4. PubMed ID: 16210080
[No Abstract] [Full Text] [Related]
16. Pompholyx of the hands after intravenous immunoglobulin therapy for clinically isolated syndrome: a paediatric case.
Brazzelli V; Grassi S; Savasta S; Ruffinazzi G; Carugno A; Barbaccia V; Marseglia GL; Borroni G
Int J Immunopathol Pharmacol; 2014; 27(1):127-30. PubMed ID: 24674688
[TBL] [Abstract][Full Text] [Related]
17. [Appropriate method of apheresis in Guillain-Barré syndrome].
Ito H; Saito T; Sakai F
Rinsho Shinkeigaku; 1999 Nov; 39(11):1168-70. PubMed ID: 10689945
[No Abstract] [Full Text] [Related]
18. Pompholyx and eczematous reactions associated with intravenous immunoglobulin therapy.
Gerstenblith MR; Antony AK; Junkins-Hopkins JM; Abuav R
J Am Acad Dermatol; 2012 Feb; 66(2):312-6. PubMed ID: 21601310
[TBL] [Abstract][Full Text] [Related]
19. High-dose intravenous immunoglobulin therapy in dysimmune neuropathies.
Nobile-Orazio E; Bersano A
Neurol Sci; 2002 Apr; 23 Suppl 1():S25-32. PubMed ID: 12032584
[No Abstract] [Full Text] [Related]
20. Human immunoglobulin and the Guillain-Barre syndrome: new indication. An alternative to plasmapheresis.
Prescrire Int; 2000 Oct; 9(49):142-3. PubMed ID: 11603414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
